Clinical research
Company shares dropped almost 10% at the news.
Although the reduction in mHTT with the drug compared to placebo was statistically significant, there was no change in total huntingtin protein (tHTT) compared to placebo.
With the holidays, it’s not surprising that it was a quiet week for clinical trial news. Nonetheless, some companies did have clinical trial stories to report. Here’s a look.
Companies from across the globe provide updates on their business and pipeline progress.
Shares of Progenics Pharmaceuticals are up more than 20% in premarket trading after the company announced positive top-line results from its Phase III prostate cancer imaging tool PyL.
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
Boston-based Stealth BioTherapeutics reported that its Phase III MMPOWER-3 clinical trial of elamipetride failed to meet its primary endpoint.
MC2 Therapeutics announced that its EU Phase 3 trial on the company’s investigational drug, Wynzora™ Cream, met its primary endpoint and that a Marketing Authorization Application is now in preparation for H1 2020.
Topas Therapeutics GmbH announced that the first patient has been enrolled in a first-in-human Phase 1 trial evaluating TPM203 in patients with pemphigus vulgaris, an orphan autoimmune disease.
Xenikos B.V. announced that the first patient has been treated in their U.S.-based Phase 3 registration trial designed to evaluate the use of T-Guard for treating steroid-refractory acute graft-versus-host disease in patients following allogeneic stem cell transplantation.
PRESS RELEASES